对转移性结直肠癌组合疗法的战略洞察力
Yoshihito Kano1, Mitsukuni Suenaga1, Hiroyuki Uetake2
1Department of Clinical Oncology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo 113-8510, Japan.
转移性结直肠癌 (mCRC) 管理正在通过组合疗法得到改善. 循环瘤DNA (ctDNA) 有助于预测复发并指导辅助化疗决策.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
- 分子生物学分子生物学
背景情况:
- 结肠直肠癌 (CRC) 是全球癌症死亡的主要原因.
- 虽然治疗切除提供了80%的5年生存率,但转移性CRC (mCRC) 的结果仍然不理想.
- 针对以前无法治疗的基因,如KRAS,为治疗提供了新的途径.
研究的目的:
- 审查目前转移性结直肠癌 (mCRC) 的管理策略.
- 探索mCRC治疗的未来前景,重点关注组合治疗方法.
- 突出循环瘤DNA (ctDNA) 在风险分层和治疗决策中的作用.
主要方法:
- 对当前mCRC管理的文献综述.
- 对组合治疗方法 (手术,化疗,向治疗,免疫治疗) 的分析.
- 讨论循环瘤DNA (ctDNA) 在术后风险分层中的应用.
主要成果:
- 组合疗法在mCRC中显示出协同作用的抗癌效应.
- ctDNA分析有效地分层了术后复发风险.
- 开发针对以前无法治疗的基因的新型药物,例如KRAS突变.
结论:
- 组合治疗策略有望改善mCRC的治疗结果.
- ctDNA分析为辅助化疗决策提供了有价值的临床信息.
- 针对性治疗的进步,包括KRAS,为mCRC患者提供了新的希望.
更多相关视频
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
08:12Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
相关概念视频
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combined Effects of Drugs: Synergism
Such synergistic combinations...
